Michael Frost

9.1k total citations · 2 hit papers
66 papers, 3.2k citations indexed

About

Michael Frost is a scholar working on Physiology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Frost has authored 66 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Physiology, 10 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Frost's work include Tuberous Sclerosis Complex Research (35 papers), Epilepsy research and treatment (8 papers) and Renal cell carcinoma treatment (7 papers). Michael Frost is often cited by papers focused on Tuberous Sclerosis Complex Research (35 papers), Epilepsy research and treatment (8 papers) and Renal cell carcinoma treatment (7 papers). Michael Frost collaborates with scholars based in United States, Germany and United Kingdom. Michael Frost's co-authors include Е. Д. Белоусова, Petrus J. de Vries, Gillian Turner, Art Daniel, John J. Bissler, Gaurav Shah, J.C. Kingswood, Tarek Sahmoud, David Lebwohl and Vicky Whittemore and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Frost

65 papers receiving 3.1k citations

Hit Papers

Everolimus for angiomyolipoma associated with tuberous sc... 2012 2026 2016 2021 2013 2012 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
    2013 629 citations John J. Bissler, J.C. Kingswood et al. The Lancet profile →
  2. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
    2012 578 citations David Neal Franz, Е. Д. Белоусова et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Frost United States 21 1.6k 694 651 629 426 66 3.2k
Vicky Whittemore United States 19 1.6k 1.0× 682 1.0× 648 1.0× 446 0.7× 373 0.9× 35 2.7k
Anna Jansen Belgium 29 620 0.4× 733 1.1× 282 0.4× 129 0.2× 697 1.6× 122 2.6k
J. Wahlström Sweden 33 627 0.4× 648 0.9× 155 0.2× 415 0.7× 556 1.3× 91 2.6k
John Osborne United Kingdom 26 1.0k 0.6× 368 0.5× 275 0.4× 309 0.5× 603 1.4× 55 3.1k
Richard P. Morse United States 19 679 0.4× 427 0.6× 100 0.2× 144 0.2× 319 0.7× 36 1.8k
Robert J. Hopkin United States 40 2.8k 1.8× 1.5k 2.2× 90 0.1× 449 0.7× 1.1k 2.7× 189 5.8k
Christine M. Eng United States 34 2.7k 1.7× 1.3k 1.9× 142 0.2× 234 0.4× 1.9k 4.3× 81 5.7k
Marguerite M. Caré United States 15 915 0.6× 549 0.8× 357 0.5× 201 0.3× 223 0.5× 38 1.9k
Michael M. Kaback United States 35 1.1k 0.7× 1.5k 2.2× 171 0.3× 416 0.7× 1.6k 3.7× 111 4.1k
Maria L. Escolar United States 33 2.0k 1.3× 917 1.3× 58 0.1× 129 0.2× 291 0.7× 121 3.4k

Countries citing papers authored by Michael Frost

Since Specialization
Citations

This map shows the geographic impact of Michael Frost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Frost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Frost more than expected).

Fields of papers citing papers by Michael Frost

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Frost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Frost. The network helps show where Michael Frost may publish in the future.

Co-authorship network of co-authors of Michael Frost

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Frost. A scholar is included among the top collaborators of Michael Frost based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Frost. Michael Frost is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lofwall, Michelle R., Edward V. Nunes, Sharon Walsh, et al.. (2025). Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial. Journal of Addiction Medicine. 19(6). 676–684. 1 indexed citations
2.
Frost, Michael, et al.. (2018). Buprenorphine Implant Removal 7 Years Postinsertion: A Case Report. Journal of Addiction Medicine. 13(1). 79–80. 2 indexed citations
3.
Rentz, Anne M., Anne Skalicky, Zhimei Liu, et al.. (2018). Burden of renal angiomyolipomas associated with tuberous sclerosis complex: results of a patient and caregiver survey. Journal of Patient-Reported Outcomes. 2(1). 30–30. 3 indexed citations
4.
Swallow, Elyse, Sarah King, Jinlin Song, et al.. (2017). Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas. Urology. 104. 110–114. 5 indexed citations
5.
Bissler, John J., David Neal Franz, Michael Frost, et al.. (2017). The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatric Nephrology. 33(1). 101–109. 28 indexed citations
6.
Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2017). Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS ONE. 12(8). e0180939–e0180939. 99 indexed citations
7.
Frost, Michael & John C. Hulbert. (2015). Clinical management of tuberous sclerosis complex over the lifetime of a patient. SHILAP Revista de lepidopterología. 6. 139–139. 7 indexed citations
8.
Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2015). Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrology Dialysis Transplantation. 31(1). 111–119. 111 indexed citations
9.
Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2015). PD35-10 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EFFICACY AND SAFETY AFTER 3.5 YEARS OF TREATMENT IN THE EXIST-2 STUDY. The Journal of Urology. 193(4S). 2 indexed citations
10.
Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2014). Everolimus Long-Term Efficacy and Safety for the Treatment of Subependymal Giant Cell Astrocytoma (SEGA) Associated With Tuberous Sclerosis Complex (TSC) (S42.007). Neurology. 82(10_supplement). 1 indexed citations
11.
Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2014). Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. The Lancet Oncology. 15(13). 1513–1520. 127 indexed citations
12.
Kingswood, J.C., Sergiusz Jóźwiak, Е. Д. Белоусова, et al.. (2014). The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrology Dialysis Transplantation. 29(6). 1203–1210. 62 indexed citations
13.
Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2014). PD17-01 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EXIST-2 LONG-TERM EFFICACY AND SAFETY. The Journal of Urology. 191(4S). 1 indexed citations
14.
15.
Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2013). Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 381(9869). 817–824. 629 indexed citations breakdown →
16.
Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2012). Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. 381(9861). 125–132. 578 indexed citations breakdown →
17.
Parker, Whitney E., Ksenia Orlova, Gregory G. Heuer, et al.. (2011). Enhanced Epidermal Growth Factor, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor Expression in Tuberous Sclerosis Complex. American Journal Of Pathology. 178(1). 296–305. 32 indexed citations
18.
Wheless, James W., Lionel Carmant, Martina Bebin, et al.. (2008). Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 50(2). 195–205. 85 indexed citations
19.
Gaussoin, Roch E., et al.. (2002). Nitrogen, Phosphorus, and Potassium Effects on Seeded Buffalograss Establishment. HortScience. 37(2). 371–373. 14 indexed citations
20.
Frost, Michael, John R. Gates, Sandra L. Helmers, et al.. (2001). Vagus Nerve Stimulation in Children with Refractory Seizures Associated with Lennox–Gastaut Syndrome. Epilepsia. 42(9). 1148–1152. 185 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vicky Whittemore Breakdown of academic impact, for papers by Anna Jansen Breakdown of academic impact, for papers by J. Wahlström Breakdown of academic impact, for papers by John Osborne Breakdown of academic impact, for papers by Richard P. Morse Breakdown of academic impact, for papers by Robert J. Hopkin Breakdown of academic impact, for papers by Christine M. Eng Breakdown of academic impact, for papers by Marguerite M. Caré Breakdown of academic impact, for papers by Michael M. Kaback Breakdown of academic impact, for papers by Maria L. Escolar
Rankless by CCL
2026